Developing new cancer drugs that target specific proteins to overcome treatment resistance
A transformative drug discovery platform for allosteric kinase inhibitors
['FUNDING_R01'] · UNIVERSITY OF MINNESOTA · NIH-11078187
This study is working on new types of cancer drugs that could help people whose cancers don't respond to regular treatments, using special technology to find and develop these drugs more quickly and effectively.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MINNESOTA (nih funded) |
| Locations | 1 site (MINNEAPOLIS, UNITED STATES) |
| Trial ID | NIH-11078187 on ClinicalTrials.gov |
What this research studies
This research focuses on creating innovative drugs called allosteric kinase inhibitors (AKIs) that can effectively treat cancers resistant to standard therapies. The team at the University of Minnesota, in collaboration with Photonic Pharma, is utilizing advanced technology to screen and identify these drugs quickly and accurately. By monitoring structural changes in proteins involved in cancer, they aim to develop therapies that can better target and inhibit cancer growth. This approach could lead to more effective treatment options for patients with difficult-to-treat cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who have experienced resistance to conventional cancer therapies.
Not a fit: Patients with early-stage cancers that are responsive to standard treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new treatment options for cancer patients who currently have limited choices due to drug resistance.
How similar studies have performed: Other research has shown promise in developing allosteric inhibitors, indicating that this approach has potential for success.
Where this research is happening
MINNEAPOLIS, UNITED STATES
- UNIVERSITY OF MINNESOTA — MINNEAPOLIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LEVINSON, NICHOLAS MARK — UNIVERSITY OF MINNESOTA
- Study coordinator: LEVINSON, NICHOLAS MARK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.